Page 172 - Drug Class Review
P. 172
Page 116 of 205
Drug Effectiveness Review Project
placebo 63.2% 11.2% 4.0% 4.0% 2.4% Loss to follow-up differential high: Yes (23.3 percentage point difference) placebo 9.6% 4.0%
Authors and Year: Rockwood et al. 2001; Markowitz et al. 2003
galantamine 86.2% 32.2% 14.6% 14.9% 11.9% Post randomization exclusions: Yes (4) Overall loss to follow-up: 25% galantamine 32.9% 25.3%
ITT: Yes
NR Yes Yes Yes Fair
Final Report Update 1 ADVERSE EVENTS: Overall adverse effects reported: Nausea • Vomiting • Dizziness • Anorexia • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs
